S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Vascular Biogenics (VBLT) Stock Forecast, Price & News

+0.09 (+7.14%)
(As of 05/13/2022 06:55 PM ET)
Today's Range
50-Day Range
52-Week Range
47,300 shs
Average Volume
186,759 shs
Market Capitalization
$93.59 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

Vascular Biogenics logo

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.


Vascular Biogenics (VBLT) to Release Earnings on Tuesday
Vascular Biogenics Earnings Preview
Vascular Biogenics earnings: here's what Wall Street expects
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$770 thousand
Book Value
$0.73 per share


Net Income
$-29.92 million
Net Margins
Pretax Margin




Free Float
Market Cap
$93.59 million

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End


Overall MarketRank

1.53 out of 5 stars

Medical Sector

1005th out of 1,403 stocks

Pharmaceutical Preparations Industry

500th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

Is Vascular Biogenics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vascular Biogenics stock.
View analyst ratings for Vascular Biogenics
or view top-rated stocks.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 688,000 shares, an increase of 32.4% from the April 15th total of 519,500 shares. Based on an average daily volume of 147,600 shares, the days-to-cover ratio is presently 4.7 days. Currently, 1.5% of the company's stock are sold short.
View Vascular Biogenics' Short Interest

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Tuesday, May 17th 2022.
View our earnings forecast for Vascular Biogenics

How can I listen to Vascular Biogenics' earnings call?

Vascular Biogenics will be holding an earnings conference call on Tuesday, May 17th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) posted its earnings results on Wednesday, March, 23rd. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.04. The biopharmaceutical company earned $0.20 million during the quarter, compared to the consensus estimate of $0.20 million. Vascular Biogenics had a negative net margin of 3,895.83% and a negative trailing twelve-month return on equity of 63.08%. During the same period last year, the business posted ($0.15) EPS.
View Vascular Biogenics' earnings history

What price target have analysts set for VBLT?

4 brokers have issued 1-year target prices for Vascular Biogenics' stock. Their forecasts range from $4.00 to $7.00. On average, they expect Vascular Biogenics' stock price to reach $5.75 in the next year. This suggests a possible upside of 325.9% from the stock's current price.
View analysts' price targets for Vascular Biogenics
or view top-rated stocks among Wall Street analysts.

Who are Vascular Biogenics' key executives?
Vascular Biogenics' management team includes the following people:
  • Prof. Dror Harats M.D., CEO & Director (Age 65)
  • Dr. Eyal Breitbart Ph.D., Sr. VP of Research & Operations (Age 55)
  • Dr. Naamit Sher Ph.D., Sr. VP of Drug Devel. & Regulatory Affairs (Age 68)
  • Dr. Erez Feige M.B.A., Ph.D., Sr. VP of Bus. Operations (Age 48)
  • Mr. Amos Ron, Company Sec. (Age 67)
  • Mr. Samuel Backenroth, Chief Financial Officer (Age 38)
  • Advocate Ayelet Horn, Gen. Counsel (Age 51)
  • Deborah Scott, Managing Director of Financial Communications
  • Dr. Tami Rachmilewitz M.D., Sr. VP of Clinical Devel. (Age 52)
  • Mr. Matthew Trudeau M.Sc., Chief Commercial Officer
What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by a variety of institutional and retail investors. Top institutional investors include DLD Asset Management LP (0.79%), Envestnet Asset Management Inc. (0.05%), Advisor Group Holdings Inc. (0.05%) and Concourse Financial Group Securities Inc. (0.00%).

Which institutional investors are buying Vascular Biogenics stock?

VBLT stock was bought by a variety of institutional investors in the last quarter, including DLD Asset Management LP, Envestnet Asset Management Inc., and Advisor Group Holdings Inc..

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $1.35.

How much money does Vascular Biogenics make?

Vascular Biogenics has a market capitalization of $93.59 million and generates $770 thousand in revenue each year. The biopharmaceutical company earns $-29.92 million in net income (profit) each year or ($0.450010) on an earnings per share basis.

How many employees does Vascular Biogenics have?

Vascular Biogenics employs 41 workers across the globe.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is www.vblrx.com.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at [email protected], or via fax at 972-8993-5001.

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.